These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 30421030)

  • 1. Class II MHC antigen processing in immune tolerance and inflammation.
    Jurewicz MM; Stern LJ
    Immunogenetics; 2019 Mar; 71(3):171-187. PubMed ID: 30421030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
    Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
    Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition.
    Patel DM; Arnold PY; White GA; Nardella JP; Mannie MD
    J Immunol; 1999 Nov; 163(10):5201-10. PubMed ID: 10553040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ins and outs of MHC class II-mediated antigen processing and presentation.
    Roche PA; Furuta K
    Nat Rev Immunol; 2015 Apr; 15(4):203-16. PubMed ID: 25720354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exogenously provided peptides of a self-antigen can be processed into forms that are recognized by self-T cells.
    Barlow AK; He X; Janeway C
    J Exp Med; 1998 May; 187(9):1403-15. PubMed ID: 9565633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo MHC class II presentation of cytosolic proteins revealed by rapid automated tandem mass spectrometry and functional analyses.
    Dongre AR; Kovats S; deRoos P; McCormack AL; Nakagawa T; Paharkova-Vatchkova V; Eng J; Caldwell H; Yates JR; Rudensky AY
    Eur J Immunol; 2001 May; 31(5):1485-94. PubMed ID: 11465105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How HLA-DM works: recognition of MHC II conformational heterogeneity.
    Sadegh-Nasseri S; Chou CL; Hartman IZ; Kim A; Narayan K
    Front Biosci (Schol Ed); 2012 Jun; 4(4):1325-32. PubMed ID: 22652874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule modulators of MHC class II antigen presentation: mechanistic insights and implications for therapeutic application.
    Call MJ
    Mol Immunol; 2011 Sep; 48(15-16):1735-43. PubMed ID: 21676462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of DM on MHC class II-restricted antigen presentation can be altered by manipulation of MHC-peptide kinetic stability.
    Lazarski CA; Chaves FA; Sant AJ
    J Exp Med; 2006 May; 203(5):1319-28. PubMed ID: 16682499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition by brefeldin A of presentation of exogenous protein antigens to MHC class II-restricted T cells.
    Adorini L; Ullrich SJ; Appella E; Fuchs S
    Nature; 1990 Jul; 346(6279):63-6. PubMed ID: 2366863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presentation of a self-peptide for in vivo tolerance induction of CD4+ T cells is governed by a processing factor that maps to the class II region of the major histocompatibility complex locus.
    Fedoseyeva EV; Tam RC; Orr PL; Garovoy MR; Benichou G
    J Exp Med; 1995 Nov; 182(5):1481-91. PubMed ID: 7595218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptides bound to major histocompatibility complex molecules.
    Maffei A; Harris PE
    Peptides; 1998; 19(1):179-98. PubMed ID: 9437752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma.
    Chan JL; Tang KC; Patel AP; Bonilla LM; Pierobon N; Ponzio NM; Rameshwar P
    Blood; 2006 Jun; 107(12):4817-24. PubMed ID: 16493000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen presenting cells.
    Hamilos DL
    Immunol Res; 1989; 8(2):98-117. PubMed ID: 2659691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis.
    Turley DM; Miller SD
    J Immunol; 2007 Feb; 178(4):2212-20. PubMed ID: 17277126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.
    Svensson M; Pfeifer J; Stockinger B; Wick MJ
    Behring Inst Mitt; 1997 Feb; (98):197-211. PubMed ID: 9382741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compartmentalization of class II antigen presentation: contribution of cytoplasmic and endosomal processing.
    Li P; Gregg JL; Wang N; Zhou D; O'Donnell P; Blum JS; Crotzer VL
    Immunol Rev; 2005 Oct; 207():206-17. PubMed ID: 16181338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen processing: the gateway to the immune response.
    Kalish RS
    J Am Acad Dermatol; 1995 Apr; 32(4):640-52. PubMed ID: 7896956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The melting pot of the MHC II peptidome.
    Stern LJ; Santambrogio L
    Curr Opin Immunol; 2016 Jun; 40():70-7. PubMed ID: 27018930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective immunosuppression by administration of major histocompatibility complex (MHC) class II-binding peptides. I. Evidence for in vivo MHC blockade preventing T cell activation.
    Guéry JC; Sette A; Leighton J; Dragomir A; Adorini L
    J Exp Med; 1992 May; 175(5):1345-52. PubMed ID: 1569402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.